Gilead submits Biologics Licence Application to USFDA for Bulevirtide EP News Bureau Nov 23, 2021 If approved, Bulevirtide will be the first treatment option for adult patients in the US with chronic Hepatitis Delta Virus…
Gilead Sciences to acquire MYR GmbH EP News Bureau Dec 10, 2020 Gilead to acquire Hepcludex, a first-in-class entry inhibitor, for treatment of chronic hepatitis delta virus (HDV), after closing…
